Press Releases + New

Date	Title and Summary	View
Toggle SummaryApr 28, 2010	COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA	View HTML COLOMBIAN PRESIDENT URIBE WELCOMES PRO-PHARMACEUTICALS AND INTRODUCTION OF DAVANAT® TO COLOMBIA 20.5 KB
Toggle SummaryMar 12, 2010	PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2009 FINANCIAL RESULTS 18 KB
Toggle SummaryMar 11, 2010	PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE	View HTML PRO-PHARMACEUTICALS CLOSES $335,000 TRANCHE 15.4 KB
Toggle SummaryFeb 10, 2010	PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION	View HTML PRO-PHARMACEUTICALS RECEIVES FINAL TRANCHE OF FUNDING FROM FEDERAL GRANT; RAISES CASH POSITION TO $8 MILLION 17 KB
Toggle SummaryFeb 02, 2010	PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE	View HTML PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE 15.2 KB
Toggle SummaryDec 17, 2009	PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM Studies Demonstrate DAVANAT® Binds To Galectin-1 and Galectin-3 Receptors That Control Angiogenesis and the Tumor's Ability To Evade the Immune System	View HTML PRO-PHARMACEUTICALS ANNOUNCES SIGNIFICANT ADVANCE IN DEFINING DAVANAT®'s MECHANISM OF ACTION BASED ON EXPERIMENTS DONE AT THE UNIVERSITY OF MINNESOTA AND THE LUDWIG INSTITUTE IN BRUSSELS, BELGIUM 22.2 KB
Toggle SummaryDec 15, 2009	THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES Pro-Pharmaceuticals' DAVANAT® Targets Galectin Receptors on Cancer Cells and Removes Their Ability to Evade the Immune System	View HTML THE LUDWIG INSTITUTE AND PRO-PHARMACEUTICALS COLLABORATE TO TEST DAVANAT®'s ABILITY TO ENHANCE THE FUNCTION OF ANTI-TUMOR T LYMPHOCYTES 20.4 KB
Toggle SummaryDec 10, 2009	PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE	View HTML PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE 16.2 KB
Toggle SummaryNov 13, 2009	Pro-Pharmaceuticals Reports Third Quarter Financial Results	View HTML Pro-Pharmaceuticals Reports Third Quarter Financial Results 17.1 KB
Toggle SummaryNov 04, 2009	PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES $310,000 TRANCHE; BRINGS TOTAL TO $4.1 MILLION OF $6.0 MILLION PRIVATE PLACEMENT 16.2 KB
Toggle SummaryOct 06, 2009	PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES $325,000 TRANCHE; BRINGS TOTAL TO $3.8 MILLION OF $6.0 MILLION PRIVATE PLACEMENT 15.2 KB
Toggle SummarySep 24, 2009	PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE MAXIM GROUP GROWTH CONFERENCE	View HTML PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE MAXIM GROUP GROWTH CONFERENCE 13.7 KB
Toggle SummaryAug 26, 2009	PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE	View HTML PRO-PHARMACEUTICALS TO PRESENT A CORPORATE UPDATE AT THE RODMAN & RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE 13.7 KB
Toggle SummaryAug 24, 2009	Pro-Pharmaceuticals Appoints Arthur R. "Bobby" Greenberg to its Board of Directors	View HTML Pro-Pharmaceuticals Appoints Arthur R. "Bobby" Greenberg to its Board of Directors 16 KB
Toggle SummaryAug 14, 2009	Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results	View HTML Pro-Pharmaceuticals Reports Second Quarter and First Six Months 2009 Financial Results 19.9 KB
Toggle SummaryJul 23, 2009	COURT ISSUES JUDGMENT DISMISSING TRADE SECRET LAWSUIT AGAINST PRO-PHARMACEUTICALS	View HTML COURT ISSUES JUDGMENT DISMISSING TRADE SECRET LAWSUIT AGAINST PRO-PHARMACEUTICALS 15.5 KB
Toggle SummaryJul 17, 2009	PRO-PHARMACEUTICALS PREVAILS IN TRADE SECRET LAWSUIT Court Dismisses Claims For Lack of Prosecution	View HTML PRO-PHARMACEUTICALS PREVAILS IN TRADE SECRET LAWSUIT 17.3 KB
Toggle SummaryJul 14, 2009	PRO-PHARMACEUTICALS NAMES NOTED PHYSICIAN DR. GILBERT S. OMENN TO SCIENTIFIC ADVISORY BOARD Professor of Internal Medicine, Human Genetics and Public Health at the University of Michigan. Former CEO of the University of Michigan Health System.	View HTML PRO-PHARMACEUTICALS NAMES NOTED PHYSICIAN DR. GILBERT S. OMENN TO SCIENTIFIC ADVISORY BOARD 17 KB
Toggle SummaryJul 06, 2009	PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES $500,000 TRANCHE; BRINGS TOTAL TO $3.2 MILLION OF $6.0 MILLION PRIVATE PLACEMENT 17.7 KB
Toggle SummaryJun 24, 2009	PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS NMR Studies Further Define DAVANAT®'s Mechanism of Action with Galectin Receptors Found on Solid Tumors	View HTML PRO-PHARMACEUTICALS' CHIEF SCIENTIST PUBLISHED ARTICLES IN THREE PRESTIGIOUS PEER-REVIEWED JOURNALS 17.2 KB
Toggle SummaryMay 30, 2009	PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS	View HTML PRO-PHARMACEUTICALS REPORTS FULL YEAR and FOURTH QUARTER 2008 FINANCIAL RESULTS 18.4 KB
Toggle SummaryMay 15, 2009	Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results	View HTML Pro-Pharmaceuticals Reports First Quarter 2009 Financial Results 19.6 KB
Toggle SummaryApr 29, 2009	PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA	View HTML PRO-PHARMACEUTICALS ENGAGES PERCEPTIVE IMAGINEERING TO MARKET DAVANAT® IN CENTRAL & SOUTH AMERICA 17.1 KB
Toggle SummaryApr 15, 2009	Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated	View HTML Pro-Pharmaceuticals' DAVANAT® Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated 17.7 KB
Toggle SummaryMar 29, 2009	PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA	View HTML PRO-PHARMACEUTICALS LICENSES TO PROCAPS S.A. EXCLUSIVE MARKETING and DISTRIBUTION RIGHTS to COMMERCIALIZE DAVANAT® to TREAT CANCER in COLOMBIA, SOUTH AMERICA 20.7 KB
Toggle SummaryFeb 17, 2009	PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING	View HTML PRO-PHARMACEUTICALS POSTPONES RIGHTS OFFERING 13.3 KB
Toggle SummaryFeb 17, 2009	PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER Gil Amelio, Ph.D., Jim Czirr, Rod Martin, J.D., Peter Traber, M.D., Named to the Company's Board of Directors	View HTML PRO-PHARMACEUTICALS NAMES THEODORE D. ZUCCONI, PH.D., CHIEF EXECUTIVE OFFICER 13.3 KB
Toggle SummaryFeb 17, 2009	PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT	View HTML PRO-PHARMACEUTICALS CLOSES INITIAL $1.8 MILLION TRANCHE OF UP TO $6.0 MILLION PRIVATE PLACEMENT 13.3 KB
Toggle SummaryFeb 03, 2009	PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT	View HTML PRO-PHARMACEUTICALS UPDATES RIGHTS OFFERING: FILES AMENDED REGISTRATION STATEMENT 16.6 KB